ChronTech’s IVIN technology allows for lower vaccine doses with maintained efficacy
New studies have now shown that ChronTech’s IVIN technology is so efficacious that a far better immune response is achievable using the same or even much lower doses of DNA than when using a regular injection needle, irrespective of whether the injection is used in combination with in vivo electroporation or not. IVIN increases the number of vaccine specific T cells by more than 100% as compared to a regular needle when in combination with electroporation. Using IVIN strong immune responses can be achieved even when the dose is reduced 100-folds. The opportunity to reduce the amount of vaccine, or number of vaccinations, is one of the most important measures for an efficacious vaccine principle. All in all, this is exceedingly promising for the development of IVIN.
”To be able to reduce the vaccine doses (dose sparing) or be able to administer fewer doses and still achieve the same immune response is central within vaccine development. This is something all companies which develop vaccines strive for. We are extremely happy with the results we can achieve using IVIN”, says ChronTech’s CEO Anders Vahlne.
IVIN
A considerable problem when using DNA vaccination or DNA therapy is that DNA is poorly taken up into cells and that they thereby produce too little of the DNA product, e.g. vaccine protein after injection with a regular injection needle. Advanced electronic or mechanical equipment such as in vivo electroporation or “gene gun” are usually needed to obtain a good effect. To solve this problem in a much simpler way, ChronTech’s scientists have developed a new injection technology, which through a centred injection direction of several needles results in that the production of vaccine proteins increases as compared to what is achieved after using regular injection needles. Apart from the new needle only a regular commercially available syringe is needed to perform an efficient DNA vaccination. A patent for this technique has now been applied for. ChronTech has now further developed IVIN so that the technology can be combined with electroporation. Through this combination a much more robust DNA expression in the cell tissue is achieved as compared to using earlier techniques.
For more information, please contact:
Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB
Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@chrontech.se
About ChronTech
ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se
In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.